Pinnacle Financial Partners Inc. purchased a new stake in shares of Incyte Co. (NASDAQ:INCY) in the 2nd quarter, Holdings Channel reports. The fund purchased 3,893 shares of the biopharmaceutical company’s stock, valued at approximately $331,000.

A number of other large investors have also recently added to or reduced their stakes in INCY. Geode Capital Management LLC increased its holdings in shares of Incyte by 7.6% during the fourth quarter. Geode Capital Management LLC now owns 2,360,606 shares of the biopharmaceutical company’s stock worth $149,854,000 after buying an additional 166,510 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Incyte by 15.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 333,420 shares of the biopharmaceutical company’s stock valued at $21,200,000 after acquiring an additional 45,496 shares during the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of Incyte by 2.2% in the 1st quarter. Janney Montgomery Scott LLC now owns 10,157 shares of the biopharmaceutical company’s stock worth $874,000 after acquiring an additional 221 shares in the last quarter. Janus Henderson Group PLC grew its position in Incyte by 146.8% during the 1st quarter. Janus Henderson Group PLC now owns 109,697 shares of the biopharmaceutical company’s stock worth $9,435,000 after acquiring an additional 65,241 shares during the last quarter. Finally, Alps Advisors Inc. bought a new stake in Incyte during the 1st quarter worth approximately $408,000. Hedge funds and other institutional investors own 92.65% of the company’s stock.

Shares of NASDAQ INCY traded up $1.23 during mid-day trading on Wednesday, hitting $79.14. The company’s stock had a trading volume of 36,350 shares, compared to its average volume of 1,035,952. Incyte Co. has a one year low of $57.00 and a one year high of $89.30. The company’s fifty day simple moving average is $81.66 and its 200-day simple moving average is $81.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.61 and a quick ratio of 5.59. The stock has a market cap of $16.98 billion, a price-to-earnings ratio of 96.35 and a beta of 1.09.

Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.37. Incyte had a net margin of 15.25% and a return on equity of 17.10%. The business had revenue of $529.93 million for the quarter, compared to analyst estimates of $498.57 million. During the same period in the prior year, the business posted $0.63 earnings per share. Incyte’s revenue was up 1.6% compared to the same quarter last year. On average, sell-side analysts predict that Incyte Co. will post 1.98 EPS for the current year.

Several equities analysts have issued reports on the company. BidaskClub downgraded Incyte from a “buy” rating to a “hold” rating in a research report on Wednesday, August 28th. JPMorgan Chase & Co. restated a “buy” rating and issued a $91.00 target price on shares of Incyte in a research note on Wednesday, July 31st. JMP Securities upgraded Incyte from a “market perform” rating to an “outperform” rating and set a $107.00 target price for the company in a research note on Thursday, September 5th. Nomura lifted their price target on Incyte from $100.00 to $111.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Incyte in a research report on Monday, June 17th. One analyst has rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Incyte has a consensus rating of “Buy” and an average price target of $91.63.

In related news, EVP Steven H. Stein sold 8,357 shares of the stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $87.96, for a total value of $735,081.72. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paula J. Swain sold 2,500 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $80.96, for a total transaction of $202,400.00. Following the transaction, the executive vice president now owns 44,112 shares of the company’s stock, valued at approximately $3,571,307.52. The disclosure for this sale can be found here. Insiders have sold a total of 118,540 shares of company stock valued at $9,829,776 in the last ninety days. Company insiders own 17.10% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Recommended Story: What is an investor looking for in an SEC filing?

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.